GIE Medical

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, GIE Medical sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 2 currently recruiting later-stage tilt upper half by trial count

GIE Medical: 2 sponsored US clinical trials, 2 recruiting.

GIE Medical sponsors 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Esophageal Stricture, with 1 trials.

Mid-pack sponsor footprint

GIE Medical is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

2 total, page 1 of 1

RECRUITING Phase 3

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus

NCT05561114
RECRUITING Phase 3

Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel

NCT05561127

Phase Distribution

PhaseTrial count
Phase 3 2

Therapeutic Areas

Esophageal Stricture 1
Bowel; Stricture 1

Where GIE Medical enrollment is open (later-stage tilt)

2 recruiting of 2 indexed (100% open).

Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Esophageal Stricture (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

GIE Medical: open-pipeline peers nationwide

Peers matched on 2 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

GIE Medical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share GIE Medical1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
GIE Medical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

GIE Medical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this GIE Medical page

2 registered trials is a research-attention snapshot, not an endorsement of GIE Medical or any single study.

  • 2 of GIE Medical's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Esophageal Stricture is the condition GIE Medical studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Esophageal Stricture trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

GIE Medical pipeline card: 2 registered trials from official public datasets.Report a data error.